Bio & Pharma
PharmaResearch acquires TuringBio for digital therapeutics
The company plans to secure personnel in the DTx, integrating AI tech into aesthetic and medical businesses
By Jul 10, 2024 (Gmt+09:00)
1
Min read
Most Read
Seoul-backed K-beauty brands set to make global mark
Australian infrastructure offers compelling opportunity: QIC
Europe looms large as K-beauty brands look to blue ocean; shares rise
NPS to lift stock holdings to 55% by 2030, raising risk appetite
NPS logs 0.87% return from first-quarter investment
PharmaResearch Co., a South Korean company specializing in regenerative medicine, announced on Wednesday that it acquired TuringBio, an AI-based digital healthcare solution firm.
PharmaResearch aims to secure talent in digital therapeutics (DTx) and integrate AI technology into its aesthetic and medical businesses, enhancing its expertise and capabilities.
Founded in 2020, TuringBio is an AI-based digital healthcare solution company currently developing evidence-based depression digital therapeutics DepRx, a personalized comprehensive psychological counseling platform WeeDool utilizing generative AI, and VitalTracker, which tracks and predicts digital phenotype data necessary for the quantitative diagnosis of mental disorders.
These services are provided to hospitals and clinics.
Write to Ye-Jin Jun at ace@hankyung.com
More to Read
-
Bio & PharmaPharmaResearch pays employees $7,706 bonus for having 3rd childMar 23, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN